Amikacin
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
Rocuronium
Neuromuscular Blocker · Neuromuscular blockade in anaesthesia
Also known as Rocuronium bromide
Neuromuscular BlockerNeuromuscular blockade in anaesthesia
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Mildly prolonged maternal neuromuscular
FDA category + note
Top interactionssee all 12 →
- AmikacinSevereDatabaseDDInter
- Botulinum Toxin Type ASevereDatabaseDDInter
- Botulinum Toxin Type BSevereDatabaseDDInter
- ColistimethateSevereDatabaseDDInter
Mechanism
Non-depolarising neuromuscular blocking drugs compete with acetylcholine for receptor sites at the neuromuscular junction. Rocuronium bromide, an aminosteroid neuromuscular blocking drug, acts by blocking these receptors, thereby preventing muscle contraction and inducing muscle relaxation.
Indications
Facilitation of tracheal intubationMuscle relaxation during anaesthesia (of the abdomen and diaphragm)Relaxation of vocal cords for tracheal tube passageNeuromuscular blockade for mechanical ventilation in intensive careAdjuvant in surgical anesthesia to obtain relaxation of skeletal muscletracheal intubationmaintenance muscle relaxantfacilitate mechanical ventilation in intensive care units
Dosing
- Adult
- although duration of action is dose-dependent. Drugs with a shorter or intermediate duration of action, such as atracurium besilate and vecuronium bromide p. 1409, are more widely used than those with a longer duration of action, such as pancuronium bromide.…
- Pediatric
- Commonly administered for short procedures where only a single intubating dose is required
Pharmacokinetics
Onset
Within 2 minutes (rapid onset)
Duration
Intermediate (30-40 minutes), although duration is dose-dependent
Metabolism
little metabolized
Excretion
Hepatic elimination (plasma clearance prolonged by 30-50% in geriatric patients)
Contraindications
- Use with caution in patients with hepatic or renal dysfunction
Side effects
Common
Mild vagolytic activity (with high doses)mild vagolytic action increases HR somewhat
Serious
- No significant histamine release
Pregnancy & lactation
Pregnancy
Mildly prolonged maternal neuromuscular
Drug interactions
Botulinum Toxin Type A
Severe
Database
Clinical effect not specified
Source: DDInter
Botulinum Toxin Type B
Severe
Database
Clinical effect not specified
Source: DDInter
Colistimethate
Severe
Database
Clinical effect not specified
Source: DDInter
Gentamicin
Severe
Database
Clinical effect not specified
Source: DDInter
Kanamycin
Severe
Database
Clinical effect not specified
Source: DDInter
Netilmicin
Severe
Database
Clinical effect not specified
Source: DDInter
Paromomycin
Severe
Database
Clinical effect not specified
Source: DDInter
Plazomicin
Severe
Database
Clinical effect not specified
Source: DDInter
Polymyxin B
Severe
Database
Clinical effect not specified
Source: DDInter
Streptomycin
Severe
Database
Clinical effect not specified
Source: DDInter
Tobramycin
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Other Neuromuscular Blocker drugs
Ask House about Rocuronium
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e, BNF·Verified: 2026-05-13 · House clinical team